載入...
Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim
Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. Since Diprovocim bears no structural similarity to the canonical lipopeptide ligands of TLR2/TLR1, we...
Na minha lista:
| 發表在: | J Med Chem |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6537610/ https://ncbi.nlm.nih.gov/pubmed/30829478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b01583 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|